2017 / 04

Next Paper
DOI: 10.24075/brsmu.2017-04-03

METHOD

Modified multiplex real-time PCR for quantification of differently sized cell-free DNA fragments

Sokolova EA1,2, Khlistun IV1, Kushlinsky DN3
About authors

1 Biocode Ltd., Moscow, Russia

2 Laboratory of Paleogenomics, Faculty of Natural Sciences,
Novosibirsk State University, Novosibirsk, Russia

3 Blokhin National Medical Research Center of Oncology, Moscow

Correspondence should be addressed: Ekaterina Sokolova
Novomereschensky proezd, d. 9, str. 1, Moscow, Russia, 119619; ur.xednay@8062aeavolokos

About paper

Contribution of the authors to this work: Sokolova EA — research planning, data analysis, drafting of a manuscript; Khlistun IV — experimental work, drafting of a manuscript; Kushlinsky DN — biomaterial sampling, clinical characterization of patients, drafting of a manuscript.

Received: 2017-08-25 Accepted: 2017-08-30 Published online: 2017-10-29
|
  1. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay. Cell. 1998 Aug 7; 94 (3): 353–62.
  2. Deininger P. Alu elements: know the SINEs. Genome Biol. 2011 Dec 28; 12 (12): 236. DOI: 10.1186/gb-2011-12-12236.
  3. Zijlstra A, Mellor R, Panzarella G, Aimes RT, Hooper JD, Marchenko ND et al. A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res. 2002 Dec 1; 62 (23): 7083–92.
  4. Schneider T, Osl F, Friess T, Stockinger H, Scheuer WV. Quantification of human Alu sequences by real-time PCR — an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants. Clin Exp Metastasis. 2002; 19 (7): 571–82.
  5. Boissinot S, Sookdeo A. The Evolution of LINE-1 in Vertebrates. Genome Biol Evol. 2016 Dec 1; 8 (12): 3485–507. DOI: 10.1093/gbe/evw247.
  6. Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N et al. Serial Assessment of Human Tumor Burdens in Mice by the Analysis of Circulating DNA. Cancer Res. 2007 Oct 1; 67 (19): 9364–70. DOI: 1.1158/0008-5472.Can-06-0705.
  7. Zhou Q, Li W, Leng B, Zheng W, He Z, Zuo M et al. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016 Jun 2; 11 (6): e0155495. DOI: 10.1371/journal.pone.0155495.
  8. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001 Feb 15; 61 (4): 1659–65.
  9. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006 Sep 10; 24 (26): 4270–6. DOI: 10.1200/JCO.2006.05.9493.
  10. Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer. 2009 Jan 1; 122 (1): 138–43. DOI: 10.1002/ijc.23057.
  11. Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 2011; 6 (9): e23418. DOI: 10.1371/journal.pone.0023418.
  12. Britten RJ. Evolutionary selection against change in many Alu repeat sequences interspersed through primate genomes. Proc Natl Acad Sci U S A. 1994 Jun 21; 91 (13): 5992–6.
  13. Okonechnikov K, Golosova O, Fursov M, the UGENE team. Unipro UGENE: a unified bioinformatics toolkit. Bioinformatics. 2012 Apr 15; 28: 1166–7. DOI: 10.1093/bioinformatics/bts091.
  14. Lou X, Hou Y, Liang D, Peng L, Chen H, Ma S et al. A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: Sensitivity and specificity for the diagnosis of myocardial infarction. Int J Mol Med. 2015 Jan; 35 (1): 72–80. DOI: 10.3892/ijmm.2014.1991.
  15. Jung K, Fleischlacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta. 2010 Nov; 411 (21–22): 1611–24. DOI: 10.1016/j.cca.2010.07.032.